You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

  • Authors: Lipika Goyal, MD; Samuel Klempner, MD
  • CME / ABIM MOC Released: 3/19/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 3/19/2022, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists, gastroenterologists, and pathologists.

The goal of this activity is to improve oncologists’ ability to integrate immune checkpoint inhibitors into the care of unresectable hepatocellular carcinoma (HCC) and esophageal cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of immunotherapy in esophageal cancer
    • Clinical data for immunotherapy use in unresectable HCC
  • Have greater competence related to the
    • Identification of appropriate candidates for treatment with immune checkpoint inhibitors in patients with HCC
    • Integration of immune checkpoint inhibitors for patients with esophageal cancer


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Lipika Goyal, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Gastrointestinal Medical Oncologist
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Disclosures

    Disclosure: Lipika Goyal, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Agios Pharmaceuticals; Alentis Therapeutics AG; AstraZeneca; DSMC; Exelexis; Incyte Corporation; Sirtex Medical Ltd; Taiho Oncology Inc
    Received grants for clinical research from: Adaptimmune; Agios; Bayer; Bristol Myers Squibb; Genentech; Incyte; Leap Therapeutics; Loxo Oncology; Macrogenetics; Merck; Novartis; Nucana; QED; Taiho Oncology

  • Samuel Klempner, MD

    Assistant Professor
    Massachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Disclosure: Samuel Klempner, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BMS; Eli Lilly; Merck; Natera; Pieris
    Owns stock, stock options, or bonds from: Turning Point Therapeutics

Steering Committee

  • Jeffrey Weber, MD, PhD

    Deputy Director 
    Laura and Isaac Perlmutter Cancer Center 
    Professor of Medicine 
    NYU Grossman School of Medicine 
    New York, New York 

    Disclosures

    Disclosure: Jeffrey Weber, MD, PhD, has disclosed the following relevant financial relationships:  
    Served as an advisor or consultant for: AstraZeneca; Bristol Myers Squibb Company; Celldex; CV6; CytomX; Genentech; GlaxoSmithKline; Incyte; Merck; Novartis; Pfizer; Protean 
    Owns stock, stock options, or bonds from: Biond; CytomX; Immunomax 
    Other: Named on a PD-1 biomarker patent by Biodesix; Named on a CTLA-4 biomarker patent by Moffitt Cancer Center 

  • Ramaswamy Govindan, MD

    Professor of Medicine 
    Division of Medical Oncology  
    Washington University School of Medicine  
    Co-Director, Section of Medical Oncology  
    Siteman Cancer Center  
    Barnes-Jewish Hospital  
    St Louis, Missouri 

    Disclosures

    Disclosure: Ramaswamy Govindan, MD, has disclosed the following relevant financial relationships:  
    Served as an advisor or consultant for: Achilles; GenePlus; Horizon Pharma (Spouse) 

  • Lipika Goyal, MD, MPhil

    Assistant Professor in Medicine 
    Harvard Medical School 
    Lead of the Liver Cancer Research Program 
    Massachusetts General Hospital Cancer Center 
    Boston, Massachusetts 
     

    Disclosures

    Disclosure: Lipika Goyal, MD, MPhil, has disclosed the following relevant financial relationships:  
    Served as an advisor or consultant for: Agios; Alentis Pharma; AstraZeneca; Debiopharm; Incyte; QED; SIRTEX; Taiho 

  • Rita Nanda, MD

    Associate Professor of Medicine 
    Director, Breast Oncology Program 
    The University of Chicago Medicine 
    Chicago, Illinois 

    Disclosures

    Disclosure: Rita Nanda, MD, has disclosed the following relevant financial relationships:  
    Served as an advisor or consultant for: Clovis; G1 Therapeutics; Genentech; Immunomedics; MacroGenics; Merck; Pfizer; Seattle Genetics 
    Received grants for clinical research from: AstraZeneca; Celgene; Corcept Therapeutics; Genentech/Roche; Immunomedics; Merck; OBI Pharm, Inc; Odonate Therapeutics; Pfizer; Seattle Genetics 
    Other: G1 Therapeutics (DSMB) 

  • Brian Rini, MD

    Ingram Professor of Medicine 
    Chief of Clinical Trials 
    Vanderbilt-Ingram Cancer Center 
    Nashville, Tennessee 

    Disclosures

    Disclosure: Brian Rini, MD, has disclosed the following relevant financial relationships:  
    Served as an advisor or consultant for: 3dMedicines; Alkermes; Aravive; Arrowhead; Aveo; BMS; Compugen; Corvus; GlaxoSmithKline; Genentech/Roche; Merck; Pfizer; Shionogi; Surface Oncology; Synthorx 
    Received grants for clinical research from: AstraZeneca; Aveo; BMS; Exelixis; Genentech/Roche; Merck; Pfizer 
    Owns stock, stock options, or bonds from: PTC Therapeutics 

  • Jared Weiss, MD

    Associate Professor of Medicine 
    Lineberger Comprehensive Cancer Center 
    Section Chief 
    Thoracic and Head and Neck Oncology 
    University of North Carolina, Chapel Hill 
    Chapel Hill, North Carolina 

    Disclosures

    Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:  
    Served as an advisor or consultant for: AbbVie; AstraZeneca; Azitra; Eli Lilly; EMD Serono; G1; Jazz; Jounce; Pfizer; Saatchi 
    Received grants for clinical research from: AstraZeneca, Celgene, Immunicum, Loxo/Lilly, Merck 
    Owns stock, stock options, or bonds from: Nektar; Vesselon 

Editors

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Davecia Ragoonath-Cameron, MS, has disclosed no relevant financial relationships.

  • Jason Luis Quinones, PhD

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Jason Luis Quinones, PhD, has disclosed no relevant financial relationships.

Society for Immunotherapy of Cancer

  • Asha Karippot, MD

    Medical Oncologist and Hematologist
    Cancer Treatment Centers of America

    Disclosures

    Disclosure: Asha Karippot, MD, has disclosed no relevant financial relationships.

  • Stephanie Burmeister, MLIS

    Online Education Program Manager 

    Disclosures

    Disclosure: Stephanie Burmeister, MLIS, has disclosed no relevant financial relationships.  

  • Mary Dean, JD

    Associate Executive Director

    Disclosures

    Disclosure: Mary Dean, JD, has disclosed no relevant financial relationships.  

  • Jacqueline Gearheart

    Program Manager 

    Disclosures

    Disclosure: Jacqueline Gearhart has disclosed no relevant financial relationships.  

  • Claire Leischer, MS

    Associate Director of Online Education 

    Disclosures

    Disclosure: Claire Leischer, MS, has disclosed no relevant financial relationships.  

  • Edwin O'Sullivan, PhD

    Senior Manager of Online Education 

    Disclosures

    Disclosure: Edwin O'Sullivan, PhD, has disclosed the following relevant financial relationships:  
    Owns stock, stock options, or bonds from: Aveo Oncology 

  • Alicia Schuessler, CAE

    Director of Education 

    Disclosures

    Disclosure: Alicia Schuessler, CAE, has disclosed no relevant financial relationships.  

  • Tara Withington, CAE

    Executive Director 

    Disclosures

    Disclosure: Tara Withington, CAE, has disclosed no relevant financial relationships.  

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and Society for Immunotherapy of Cancer.

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

Authors: Lipika Goyal, MD; Samuel Klempner, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 3/19/2021

Valid for credit through: 3/19/2022, 11:59 PM EST

processing....

Editor’s Note: On March 22, 2021, the Food and Drug Administration approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.

Contents of This CME Activity

All sections of this activity are required for credit.

Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

Join Dr Goyal for a short discussion on the evolving landscape of immunotherapies for the treatment of advanced/metastatic HCC.
Lipika Goyal, MD

Unresectable HCC: Treatment With ICIs to Come

Dr Goyal provides an overview of new and emerging treatment regimens for the management of patients with unresectable HCC.
Lipika Goyal, MD

Current Treatment of Metastatic Esophageal Cancer With ICIs

Dr Klempner reviews recent approvals and key clinical data supporting the use of ICIs in the metastatic esophageal cancer setting.
Samuel Klempner, MD

Esophageal Carcinoma Treatment: Ongoing Investigations With Immune Checkpoint Inhibitors

Join Dr Klempner for a discussion on key emerging clinical trials investigating ICI regimens that are likely to impact clinical practice in the near future.
Samuel Klempner, MD
 

Educational Impact Challenge

The goal of this activity is to improve oncologists’ ability to integrate immune checkpoint inhibitors into the care of unresectable hepatocellular carcinoma (HCC) and esophageal cancer.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print